Citigroup Inc Bolt Biotherapeutics, Inc. Transaction History

Citigroup Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.85 - $1.12 $1,960 - $2,583	2,307 New	2,307 $2,000
Q4 2022 Feb 09, 2023	SELL	$1.26 - $1.48 $567 - $666	-450 Reduced 91.28%	43 $0
Q3 2022 Nov 10, 2022	SELL	$1.72 - $2.61 $627 - $952	-365 Reduced 42.54%	493 $1,000
Q2 2022 Aug 10, 2022	SELL	$1.41 - $2.91 $10,391 - $21,446	-7,370 Reduced 89.57%	858 $2,000
Q1 2022 May 12, 2022	BUY	$2.74 - $4.82 $2,718 - $4,781	992 Added 13.71%	8,228 $22,000

Q4 2021 Feb 10, 2022	BUY	$4.19 - $13.97 $18,410 - $61,384	4,394 Added 154.61%	7,236 $35,000
Q3 2021 Nov 10, 2021	BUY	$11.15 - $18.6 $31,688 - $52,861	2,842 New	2,842 $36,000

24.3M

Ticker BOLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,641,500
Market Cap $28.2M
Description
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.